- Medigene to Present at Upcoming Scientific Conferences
- Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
- Medigene AG Secures European Patent for its iM-TCR Technology
- Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
- Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Medigene AG to report full year 2023 financial results on March 28, 2024
- Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
- Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
- Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
- Medigene to Present at Upcoming Conferences
More ▼
Key statistics
On Thursday, Medigene AG (MDG1X:GER) closed at 1.93, 42.59% above the 52 week low of 1.35 set on Dec 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.84 |
---|---|
High | 2.03 |
Low | 1.82 |
Bid | -- |
Offer | -- |
Previous close | 1.93 |
Average volume | 19.53k |
---|---|
Shares outstanding | 24.56m |
Free float | 23.69m |
P/E (TTM) | -- |
Market cap | 45.32m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 18 2024 16:36 BST.
More ▼